Luqa Pharmaceuticals Gains China Rights To Women's Anti-Fungal

Shanghai's Luqa Pharma in-licensed China rights to Macmiror (Nifuratel), a product used to treat a wide range of infections in the genito-urinary tract. Luqa specifically mentioned vulvovaginal infections due to the pathogenic micro-organisms. Luqa did not identify the maker of the product or specify other details of the transaction. A division of Spain's Almirall, Luqa in-licenses products for China, focusing on dermatological products and women's health. Earlier this month, Luqa acquired Arista Pharma, also a China dermatological company.

Back to news